Schedule 13D ownership disclosure

KALARIS THERAPEUTICS INC

Common Stock, $0.0001 par value per share · CUSIP: 482929106

Event date: 2025-03-18

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Samsara BioCapital, L.P.Reported CIK 0001699737

    Shares: 11,448,081.00 · Class: 61.2%

  • Samsara BioCapital GP, LLCReported CIK 0001888829

    Shares: 11,448,081.00 · Class: 61.2%

  • Srinivas AkkarajuReported CIK 0001253170

    Shares: 11,448,081.00 · Class: 61.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001415889-25-008979
Form type
SCHEDULE 13D
Filer
Kalaris Therapeutics, Inc.
CIK
CIK 1754068
Filed
Mar 25, 2025
Reporting period
Mar 18, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub